九州通品牌怎么样 申请店铺

我要投票 九州通在减肥药行业中的票数:886 更新时间:2026-01-30
九州通是哪个国家的品牌?「九州通」是 九州通医药集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘宝林在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九州通品牌出海!将品牌入驻外推网,定制九州通品牌推广信息,可以显著提高九州通产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

九州通怎么样

九州通医药集团股份有限公司是一家以药品、医疗器械、生物制品、保健品等产品批发、零售连锁、药品生产与研发及有关增值服务为核心业务的大型企业集团。

截至2012年12月31日,九州通医药集团拥有总资产148.04亿元,员工9,148人,下属公司80余家,直营和加盟的零售连锁药店875家。2012年,九州通医药集团实现营业收入295.08亿元,上缴税收近5亿元。

九州通医药集团拥有完善的品种结构和丰富的客户资源,经营品规达160,000多个,上游供货商5,600家,下游客户70,000多家,取得了国内131种药品的全国或区域总经销或总代理资格。至今为止,九州通医药集团已在全国22个省会城市设立了22家省级子公司(大型医药物流中心)、在29个地级市设立了29家地级公司(地区医药物流配送中心)及400多个终端配送点,形成了覆盖全国大部分县级行政区域的物流配送网络。

打造企业核心竞争力,九州通医药集团秉持“技术让服务更卓越”的理念,致力于现代物流技术和信息技术的开发和应用。目前,九州通医药集团是国内唯一具备独立整合物流规划、物流实施、系统集成能力的医药分销企业,并取得了20多项自主知识产权,在现代物流技术和信息技术方面处于国内领先、国际一流的地位,是国内医药行业唯一获得“中国物流改革开放30年旗帜企业”称号的企业。

九州通医药集团具备向上下游客户提供需求解决方案及增值服务的能力,并逐渐将技术增值服务延伸到了上下游产业链,形成了独具特色的物流管理、供应链管理、医院管理三大产品线,可以满足客户对技术的最高要求。

近年来,九州通医药集团曾获得“国家5A级物流企业”、“湖北省最具影响力民营企业”、“湖北省守合同重信用企业”、“中国社会责任感优秀企业”、“全国非公有制企业双强百佳党组织”等多项荣誉。

未来,九州通医药集团将顺应医药市场变革,继续坚持以医药分销为核心业务,以医院纯销、中药材、医疗器械、零售连锁为战略业务,以物流技术营销、电子商务、国际贸易、原料药等为新兴业务的业务组合战略;扩大和完善医药营销网络布局,不断为医药健康产业提供高性价比服务,努力将九州通打造成为中国医药健康产业最佳服务商。

JIUZHOUTONG Pharmaceutical Group Co., Ltd. is a large-scale enterprise group with the core business of wholesale, retail chain, drug production and R & D and related value-added services of drugs, medical devices, biological products, health products and other products. As of December 31, 2012, JIUZHOUTONG Pharmaceutical Group has a total assets of 14.804 billion yuan, 9148 employees, more than 80 subordinate companies, 875 retail chain drugstores directly operated and joined. In 2012, JIUZHOUTONG Pharmaceutical Group achieved an operating revenue of 29.508 billion yuan and turned in tax revenue of nearly 500 million yuan. JIUZHOUTONG Pharmaceutical Group has a complete variety structure and rich customer resources. It operates more than 160000 products, 5600 upstream suppliers and 70000 downstream customers. It has obtained the qualification of national or regional general distribution or general agent of 131 kinds of drugs in China. So far, JIUZHOUTONG Pharmaceutical Group has set up 22 provincial subsidiaries (large pharmaceutical logistics centers) in 22 provincial capitals, 29 prefecture level companies (regional pharmaceutical logistics distribution centers) and more than 400 terminal distribution points in 29 prefecture level cities, forming a logistics distribution network covering most county-level administrative regions of the country. To build the core competitiveness of the enterprise, JIUZHOUTONG Pharmaceutical Group adheres to the concept of "technology makes service more excellent", and is committed to the development and application of modern logistics technology and information technology. At present, JIUZHOUTONG Pharmaceutical Group is the only pharmaceutical distribution enterprise in China that has the ability to independently integrate logistics planning, logistics implementation and system integration, and has obtained more than 20 independent intellectual property rights. It is in the leading position in modern logistics technology and information technology in China and the first-class position in the world. It is the only one in the domestic pharmaceutical industry that has won the title of "30 years banner enterprise of China's logistics reform and opening up" Enterprises. JIUZHOUTONG Pharmaceutical Group has the ability to provide demand solutions and value-added services to upstream and downstream customers, and gradually extends technology value-added services to the upstream and downstream industrial chains, forming a unique logistics management, supply chain management, hospital management three product lines, which can meet the highest requirements of customers for technology. In recent years, JIUZHOUTONG Pharmaceutical Group has won many honors, such as "national 5A level logistics enterprise", "the most influential private enterprise in Hubei Province", "Hubei Province contract abiding and trustworthy enterprise", "China's outstanding enterprise of social responsibility", "national top 100 Party organizations of non-public enterprises". In the future, JIUZHOUTONG Pharmaceutical Group will continue to adhere to the core business of pharmaceutical distribution, the strategic business of hospital pure sales, Chinese herbal medicine, medical devices, retail chain, the business combination strategy of logistics technology marketing, e-commerce, international trade, API and other emerging businesses, expand and improve the layout of pharmaceutical marketing network, and continue to serve the medical health The industry provides cost-effective services and strives to build Jiuzhoutong into the best service provider in China's pharmaceutical and health industry.

本文链接: https://brand.waitui.com/02808d9a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

市场监管总局公布4起直播电商领域典型案例,成都快购被罚超2600万

36氪获悉,市场监管总局今天(30日)集中发布第五批直播电商领域典型案例。其中,市场监管总局查处成都快购科技有限公司违法案。2025年12月,市场监管总局综合考量当事人的违法事实、案件性质、违法情节以及社会危害程度,依法对当事人的违法行为作出行政处罚。责令当事人立即改正违法行为,并处罚没款26692904.62元。

2小时前

新易盛:2025年净利同比预增231.24%-248.86%

36氪获悉,新易盛发布2025年业绩预告。报告显示,预计2025年归属于上市公司股东的净利润为94亿元-99亿元,比上年同期增长231.24%-248.86%。报告期内,受益于算力投资持续增长,高速率产品需求快速提升,公司销售收入和净利润大幅增加。

2小时前

莫高股份:公司股票可能被实施退市风险警示

36氪获悉,莫高股份公告,经公司财务部门初步测算,预计公司2025年年度利润总额、净利润或者扣除非经常性损益后的净利润孰低者为负值,且扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于3亿元。公司股票在2025年年度报告披露后可能被实施退市风险警示(在公司股票简称前冠以“*ST”字样)。

2小时前

荃银高科:涉嫌信息披露违法违规,被中国证监会立案调查

36氪获悉,荃银高科公告,公司于2026年1月30日收到中国证监会下发的《立案告知书》,因公司涉嫌信息披露违法违规,中国证监会决定对公司立案。目前公司生产经营正常,立案调查不会对公司正常生产经营活动产生重大影响。公司将积极配合中国证监会的工作,严格履行信息披露义务。

2小时前

追觅科技亮相2026中英企业家委员会会议

1月29日,2026中英企业家委员会会议在京举行,追觅科技作为行业代表受邀参会。追觅科技创立于2017年,目前业务已覆盖全球超120个国家和地区,开设超6500家旗舰店。在英国市场,其扫地机品类市占率近30%,伯明翰旗舰店位于核心商圈New Street。此次受邀参与会议,彰显其全球化实力与品牌国际影响力,将进一步助力其全球智能生态布局。

2小时前

本页详细列出关于九州通的品牌信息,含品牌所属公司介绍,九州通所处行业的品牌地位及优势。
咨询